Clinical description of 44 patients with acute promyelocytic leukemia who developed the retinoic acid syndrome
about
Pathophysiology, clinical features and radiological findings of differentiation syndrome/all-trans-retinoic acid syndromeThe regulatory role of cell mechanics for migration of differentiating myeloid cells.Cancer therapy and cardiotoxicity: the need of serial Doppler echocardiography.Does microgranular variant morphology of acute promyelocytic leukemia independently predict a less favorable outcome compared with classical M3 APL? A joint study of the North American Intergroup and the PETHEMA GroupPhase 1 trial and pharmacokinetic study of arsenic trioxide in children and adolescents with refractory or relapsed acute leukemia, including acute promyelocytic leukemia or lymphoma.Development of a nanoparticulate formulation of retinoic acid that suppresses Th17 cells and upregulates regulatory T cellsSivelestat relieves respiratory distress refractory to dexamethasone in all-trans retinoic acid syndrome: a report of two casesA Complicated Case of Acute Promyelocytic Leukemia in the Second Trimester of Pregnancy Successfully Treated with All-trans-Retinoic AcidDifferentiation syndrome in promyelocytic leukemia: clinical presentation, pathogenesis and treatment.The differentiation syndrome in patients with acute promyelocytic leukemia: experience of the pethema group and review of the literaturePregnancy-induced hypertension caused by all-trans retinoic acid treatment in acute promyelocytic leukemia.Relationship between obesity and clinical outcome in adults with acute myeloid leukemia: A pooled analysis from four CALGB (alliance) clinical trialsEmerging new approaches for the treatment of acute promyelocytic leukemia.Acute Coronary Syndrome Manifesting as an Adverse Effect of All-trans-Retinoic Acid in Acute Promyelocytic Leukemia: A Case Report with Review of the Literature and a Spotlight on Management.Mesenchymal stem cells induce granulocytic differentiation of acute promyelocytic leukemic cells via IL-6 and MEK/ERK pathways.Molecular approaches to sarcoma therapy.Infiltrative lung diseases: complications of novel antineoplastic agents in patients with hematological malignancies.Evidence for Clinical Differentiation and Differentiation Syndrome in Patients With Acute Myeloid Leukemia and IDH1 Mutations Treated With the Targeted Mutant IDH1 Inhibitor, AG-120.Developing a Novel Indolocarbazole as Histone Deacetylases Inhibitor against Leukemia Cell Lines.Late differentiation syndrome in acute promyelocytic leukemia: a challenging diagnosis.Podocyte Regeneration Driven by Renal Progenitors Determines Glomerular Disease Remission and Can Be Pharmacologically Enhanced.Multiple nodular and patchy infiltrations in a 34-year-old male.Differentiation Syndrome Associated With Enasidenib, a Selective Inhibitor of Mutant Isocitrate Dehydrogenase 2: Analysis of a Phase 1/2 Study.Two cases of differentiation syndrome with ocular manifestations in patients with acute promyelocytic leukaemia treated with all-trans retinoic acid and arsenic trioxide.Retinoic acid syndrome in a elderly male with psoriasis- A case report.Evolving Treatment Strategies for Elderly Leukemia Patients with IDH Mutations.Invasive Fungal Infections in Acute Promyelocytic Leukemia on Dual Differentiating Agents: Real World Data
P2860
Q27012691-92566C2C-3BB0-4B56-A857-44D7C215EEADQ30490345-0656FDFC-7D7B-4E28-9EAF-15FC7051F3E9Q30500830-B316B9B4-0FF0-48FE-8898-AE7964ED9694Q34541742-9F24A151-567F-4B3C-9688-B3155C880694Q34584174-4E4D4642-B9FE-4604-B884-0CFC311CD65EQ34707563-A0D70FB7-D40F-415B-B362-D95525E2704DQ35103848-B94878AC-726C-40A0-AE2A-F9FF124458BCQ35188054-1C1F5909-69BC-4192-86CB-E4E47FA8B76DQ35560264-406CC4E5-F329-4E02-8A97-D33BA2F380E9Q35640755-8744D954-D523-47C6-8C60-43361845635CQ35803863-A34DC3B2-7B7E-432A-9927-D1B966EDA9CDQ36494308-8681BEB3-F555-49F7-A9DE-3200A247AA2FQ36612619-899B35FE-4586-42B6-A55E-B976336EF454Q36615355-797E6983-91A8-4D3E-8E5A-EECCCB4F3911Q36936676-5E000303-F0E9-432D-B2DA-889238F0DD1FQ37180948-9ABBB809-123B-42BA-A53A-136E2A19578CQ37190474-258E4812-0608-4E5B-9D6F-83EB4C5E5FECQ40103401-E0CB92E8-CDBA-4E8B-B8D0-CEBAE09B0FB3Q41065264-A467A567-2358-4C40-AC2C-3A9AAD9A998FQ42071044-57C20DA0-243C-4BE1-8F0B-8C3BF7528F66Q42107349-5CFA7F34-EBF2-4F9F-AB83-EA8310D5330EQ43063877-CF0687F5-603C-4412-BBC1-BC737F8314C8Q47561019-7123E94D-52DC-4CF3-94D4-A02C789C26ABQ50281099-C1C16B43-F6D8-4D84-BB95-2DC69B50EEF4Q55422522-6C1A0465-F9B5-4F02-99FA-C24E79D2FE0BQ55515402-7753E58D-EA49-4DBC-AD93-8791B08477FAQ56529827-AADF4C7C-8F68-4178-BA3F-8A99DCC90200
P2860
Clinical description of 44 patients with acute promyelocytic leukemia who developed the retinoic acid syndrome
description
2000 nî lūn-bûn
@nan
2000 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年学术文章
@wuu
2000年学术文章
@zh-cn
2000年学术文章
@zh-hans
2000年学术文章
@zh-my
2000年学术文章
@zh-sg
2000年學術文章
@yue
name
Clinical description of 44 pat ...... ped the retinoic acid syndrome
@ast
Clinical description of 44 pat ...... ped the retinoic acid syndrome
@en
Clinical description of 44 pat ...... ped the retinoic acid syndrome
@nl
type
label
Clinical description of 44 pat ...... ped the retinoic acid syndrome
@ast
Clinical description of 44 pat ...... ped the retinoic acid syndrome
@en
Clinical description of 44 pat ...... ped the retinoic acid syndrome
@nl
prefLabel
Clinical description of 44 pat ...... ped the retinoic acid syndrome
@ast
Clinical description of 44 pat ...... ped the retinoic acid syndrome
@en
Clinical description of 44 pat ...... ped the retinoic acid syndrome
@nl
P2093
P1433
P1476
Clinical description of 44 pat ...... ped the retinoic acid syndrome
@en
P2093
Andersen JW
Feusner JH
François C
Schiffer CA
Shepherd L
Tallman MS
Wiernik PH
P407
P577
2000-01-01T00:00:00Z